Download MendeleyIdentification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases.
Bach, J., Eastwood, P., Gonzalez, J., Gomez, E., Alonso, J.A., Fonquerna, S., Lozoya, E., Orellana, A., Maldonado, M., Calaf, E., Alberti, J., Perez, J., Andres, A., Prats, N., Carreno, C., Calama, E., De Alba, J., Calbet, M., Miralpeix, M., Ramis, I.(2019) J Med Chem 62: 9045-9060
- PubMed: 31609613
- DOI: https://doi.org/10.1021/acs.jmedchem.9b00533
- Primary Citation of Related Structures:
6HZU, 6HZV - PubMed Abstract:
Janus kinases (JAKs) have a key role in regulating the expression and function of relevant inflammatory cytokines involved in asthma and chronic obstructive pulmonary disease. Herein are described the design, synthesis, and pharmacological evaluation of a series of novel purinone JAK inhibitors with profiles suitable for inhaled administration. Replacement of the imidazopyridine hinge binding motif present in the initial compounds of this series with a pyridone ring resulted in the mitigation of cell cytotoxicity. Further systematic structure-activity relationship (SAR) efforts driven by structural biology studies led to the discovery of pyridone 34 , a potent pan-JAK inhibitor with good selectivity, long lung retention time, low oral bioavailability, and proven efficacy in the lipopolysaccharide-induced rat model of airway inflammation by the inhaled route.
